Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has been ...

Pfizer's revenue rose by 10% last quarter, exceeding market expectations. The drugmaker has been cutting costs, which has paid off at the bottom line. However, the industry is feeling government ...

WASHINGTON — A key Republican senator on health issues and the CEO of Pfizer said the effort known as Operation Warp Speed under President Donald Trump to rapidly create and disseminate COVID-19 ...

Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly. 10 stocks we like better than ...